
X
Sanofi gets opt-in rights to two Regeneron cancer drugs
https://pharmaphorum.com/news/sanofi-gets-opt-in-rights-to-two-regeneron-cancer-drugs/
Pfizer and Eli Lilly are competitors in NGF research
Deal combines Regeneron’s receptor tech with CAR-T biotech’s expertise
But Sanofi/Regeneron could have advantage thanks to price cut and better data